VIVEbiotech Drives Innovation in Lentiviral Vectors with New Pseudotypes
Application in in-vivo and ex-vivo therapies to enhance tropism, efficacy, and transduction efficiency
Marie Fertin, Chief of Custom Solution and Process Development at VIVEbiotech, presents in this video our capabilities in the manufacturing of lentiviral vectors with new pseudotypes. Pseudotyping enables the modification of vector tropism, which can improve the efficacy and safety of in-vivo therapies.
At VIVEbiotech, we currently support 12 in-vivo programs, two of which are already in clinical phase. This strategy is also valuable in ex-vivo therapies, as it improves transduction efficiency.
Our goal is to support our partners in advancing their programs into later clinical phases and achieving greater impact on patients’ lives.
👉 You can watch the full video featuring Marie Fertin on our YouTube channel or on LinkedIn.